Probiotic vaccines and related methods of use
AssigneeSalvitus, Inc.
InventorGeorge PIECZENIK
Life of this patent
Estimating the term…
Abstract
Provided herein are probiotic vaccines comprising, a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of: LPESFDGDPASNTAPLQPEQLQVF “SEQ ID NO:1; HER2”. In particular embodiments of the invention vaccine, the exogenous peptide epitope is functionally expressed on a coat protein selected from the group consisting of: pill, pVI, pVII, pVIII and pIX. Also provided herein are methods of preventing or treating cancer, comprising administering to a patient in need thereof, one or more of the probiotic vaccines provided herein: or one or more of the recombinant phages provided herein
Claims25
A probiotic vaccine comprising,
- a recombinant filamentous phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of:
- (SEQ ID NO:
- 1;
- HER2)
- LPESFDGDPASNTAPLQPEQLQVF,
- (SEQ ID NO:
- 2;
- HER2)
- PESFDGDPASNTAPLQPEQLQ,
- (SEQ ID NO:
- 3;
- CD38)
- QPEKVQTLEAWVIHGG,
- (SEQ ID NO:
- 4;
- CD38)
- ISKRNIQFSCKNIYR,
- (SEQ ID NO:
- 5;
- CD38)
- TFGSVEVHNL,
- (SEQ ID NO:
- 6;
- CD38)
- QTLEA,
- (SEQ ID NO:
- 7;
- CD38)
- IQFSC,
- and
- (SEQ ID NO:
- 8;
- PD-1)
- AFPEDRSQPG.
- and
- a bacteria infected with said recombinant phage.
A recombinant filamentous phage genome comprising
- a recombinant phage genome comprising a nucleic acid encoding a polypeptide comprising an exogenous peptide epitope, or fragments or variants thereof, selected from the group consisting of:
- (SEQ ID NO:
- 1;
- HER2)
- LPESFDGDPASNTAPLQPEQLQVF,
- (SEQ ID NO:
- 2;
- HER2)
- PESFDGDPASNTAPLQPEQLQ,
- (SEQ ID NO:
- 3;
- CD38)
- QPEKVQTLEAWVIHGG,
- (SEQ ID NO:
- 4;
- CD38)
- ISKRNIQFSCKNIYR,
- (SEQ ID NO:
- 5;
- CD38)
- TFGSVEVHNL,
- (SEQ ID NO:
- 6;
- CD38)
- QTLEA,
- (SEQ ID NO:
- 7;
- CD38)
- IQFSC,
- and
- (SEQ ID NO:
- 8;
- PD-1)
- AFPEDRSQPG;
A method of preventing or treating breast, bladder, pancreatic, ovarian, and/or stomach cancer, comprising administering, to a patient in need thereof, a recombinant phage or probiotic vaccine comprising at least one exogenous peptide epitope, or fragment or veriant thereof, selected from:
- LPESFDGDPASNTAPLQPEQLQVF (SEQ ID NO:1), or PESFDGDPASNTAPLQPEQLQ (SEQ ID NO:2).
A method of preventing or treating leukemia, lymphoma, myeloma, multiple myeloma, and/or chronic lymphocytic leukemia (CLL), comprising administering, to a patient in need thereof, a recombinant phage or probiotic vaccine comprising at least one exogenous peptide epitope, or fragment or veriant thereof, selected from:
- (SEQ ID NO:
- 3)
- QPEKVQTLEAWVIHGG,
- (SEQ ID NO:
- 4)
- ISKRNIQFSCKNIYR,
- (SEQ ID NO:
- 5)
- TFGSVEVHNL,
- (SEQ ID NO:
- 6)
- QTLEA,
- and
- (SEQ ID NO:
- 7)
- IQFSC.
A method of preventing Korean Fever Virus infection, comprising administering, to a patient in need thereof, a recombinant phage or probiotic vaccine comprising at least one exogenous peptide epitope, or fragment or veriant thereof, selected from:
- QPEKVQTLEAWVIHGG (SEQ ID NO:3), ISKRNIQFSCKNIYR (SEQ ID NO:4), TFGSVEVHNL (SEQ ID NO:5), QTLEA (SEQ ID NO:6), and IQFSC (SEQ ID NO:7).
A method of preventing or treating cancer, comprising administering, to a patient in need thereof, a recombinant phage or probiotic vaccine comprising at least one exogenous peptide epitope corresponding to AFPEDRSQPG (SEQ ID NO:8), or fragments or variants thereof;
- wherein cancer is selected from the group consisting of:
- gastric cancer, melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial carcinoma, non-muscle invasive bladder cancer [NMIBC]), colon or rectal cancer, esophageal or certain gastroesophageal junction (GEJ) carcinomas, cervical cancer, renal cell carcinoma (RCC), advanced endometrial carcinoma, cutaneous squamous cell carcinoma (cSCC), and/or triple-negative breast cancer (TNBC).
Dependencies are inferred from the claim text.